Choueiri Discusses Results of CLEAR Substudy of Lenvatinib Plus Pembrolizumab in RCC

Video

At 2022 ASCO GU, Toni K. Choueiri, MD, discussed the CLEAR study and how East Asian patients with renal cell carcinoma derived similar benefit with lenvatinib plus pembrolizumab as the overall trial population.

During the 2022 Genitourinary Cancers Symposium, CancerNetwork® spoke with Toni K. Choueiri, MD, director of Lank Center for Genitourinary Oncology and director of the Kidney Cancer Center at Dana-Farber Cancer Institute as well as Jerome and Nancy Kohlber Chair and Professor of Medicine at Harvard Medical School, about the CLEAR study (NCT02811861).1 This current analysis examined the safety of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) vs sunitinib (Sutent) in a subgroup of East Asian patients with advanced renal cell carcinoma.

Transcript:

The CLEAR study was the first 3-arm study of the doublet of lenvatinib plus pembrolizumab or lenvatinib/everolimus versus sunitinib as standard of care. This led to lenvatinib plus pembrolizumab being approved based on, not just the PFS [progression-free survival], but an OS [overall survival] and response rate benefit.2 There were always questions since we started using target therapy, for over a decade now, if Asian patients will have a different profile, activity, or efficacy, but there was none here in the study. Lenvatinib plus pembrolizumab benefited patients from Asia and there was no difference compared to overall population.

References

1. Young Rha S, Choueiri TK, Matveev VB, et al. Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. J Clin Oncol. 2022;40(suppl 6):338. doi 10.1200/JCO.2022.40.6_suppl.338

2. FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma. News Release. FDA. August 10, 2021. Accessed March 1, 2022. https://bit.ly/3K5b3lZ

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content